Last update Oct. 12, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
オルリスタット is Orlistat in Japanese.Is written in other languages:
オルリスタット belongs to these groups or families:
Main tradenames from several countries containing オルリスタット in its composition:
|Oral Bioavail.||≈ 0||%|
|T½||1 - 2||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a gastric and pancreatic lipase inhibitor that limits the absorption of dietary fat by 30% (Guerciolini 1997). Oral administration three times a day.
At latest update, relevant information on excretion into breast milk was not found.
However, because of pharmacokinetic data (a moderately high molecular-weight, a virtually nil absorption, and very high protein-binding-capacity), excretion of Orlistat into breast milk in significant levels is unlikely.
Orlistat has virtually no intestinal absorption (Zhi 1995). Plasma (AEMPS 2014) and breast milk (Musatadi 2021) concentrations have been found at insignificant levels (<10 and <3 micrograms/L, respectively).
On long-standing basis, it may affect absorption of liposoluble vitamins (A, D, E, K), beta-carotenes and colesterol (Mittendorfer 2001, Melia 1996). This would be a reason to recommend a varied diet which should be rich in consumption of fruits, vegetables. Vitamin supplementation should also be considered. Nutritional status of the nursing mother should be monitored.
Expert authors consider the use of orlistat to be safe or very probably safe during breastfeeding. (Hale, LactMed, Briggs 2015)
There is good quality evidence that exclusive breastfeeding helps to regain pre-pregnancy weight earlier than if breastfeeding is partial (mixed) or there is no breastfeeding, and that prolonged breastfeeding helps maintain that loss and as well as body fat loss.(Jayasinghe 2021, Schalla 2017, López 2016, Jarlenski 2014, Sámano 2013, Neville 2014, Hatsu 2008, Dewey 2004, 2001 y 1993, Kramer 1993)